On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 5 of 111 Study Duration  • Patients will complete  a single dose of OTL38  initiation of 
intraoperative imaging.  
• Safety assessments: during infusion of OTL38; post- surgery; Day 7 (± 4), and Day 
28 (± 7) after surgery.  
• Estimated t otal length of study: 18 months 
• Patient accrual estimate: 12 months  
Eligibility 
Criteria  Inclusion:  
1. Male and Female patients 18 years of age and older 
2. Confirmed diagnosis of adenocarcinoma lung cancer 
OR, 
3. Have a primary diagnosis, or at high clinical suspicion, of lung nodule(s) 
warranting surgery based on CT and/or PET imaging 
4. Who are scheduled to undergo endoscopic or thoracic surgery 
5. A negative serum pregnancy test at Screening followed by a negative urine 
pregnancy test on the day of surgery or day of admission for female patients of 
childbearing potential 
6. Female patients of childbearing potential or less than 2 years postmenopausal 
agree to use an acceptable form of contraception from the time of signing 
informed consent until 30 days after study completion 
7. Ability to understand the requirements of the study, provide written informed 
consent and authorization of use and disclosure of protected health information, 
and agree to abide by the study restrictions and to return for the required assessments  
Exclusion:  
1. Previous exposure to OTL38 
2. Known FR-negative lung nodules 
3. Any medical condition that in the opinion of the investigators could potentially 
jeopardize the safety of the patient  
4. History of anaphylactic reactions  
5. History of allergy to any of the components of OTL38, including folic acid 
6. Pregnancy, or positive pregnancy test  
7. Clinically significant abnormalities on electrocardiogram (ECG) at scr eening.  
8. Presence of any psychological, familial, sociological or geographical condition 
potentially hampering compliance with the study protocol and follow-up 
schedule  
9. Impaired renal function defined as eGFR< 50 mL/min/1.73m2 
10. Impaired liver function define d as values > 3x the upper limit of normal (ULN) 
for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), or total bilirubin. 
11. Received an investigational agent in another investigational drug or vaccine trial 
within 30 days prior to surgery 
12. Known sensitivity to fluorescent light  
Number of 
Subjects  Up to 110 patients with suspected lung cancer will be enrolled in this study  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 15 of 111 Table of Contents 
1 PROTOCOL SYNOPSIS .......................................................................................................4  
2 SCHEDULE OF PROCEDURES  .......................................................................................14  
3 BACKGROUND INFORMATI ON ....................................................................................19  
3.1 Background ..................................................................................................................19  
3.2 Rationale  ......................................................................................................................19  
3.3 Investigational Product ................................................................................................20  
3.3.1  Prior Clinical Expe rience ...............................................................................20  
3.3.2  Phase 1b Ovarian Cancer Study (CHDR1321- B) ..........................................20  
3.3.3  Phase 2 Ovarian Cancer Study (OTL -2016- OTL38 -003) ..............................21  
3.3.4  Early Clinical Experience with Lung and Pituitary patients: .........................21  
3.4 Risks and Benefits of OTL38 ......................................................................................22  
3.4.1  Risks ...............................................................................................................22  
3.4.2  Benefits  ...........................................................................................................23  
4 STUDY OBJECTIVES  ........................................................................................................24  
4.1 Primary  .........................................................................................................................24  
4.2 Secondary  .....................................................................................................................24  
4.3 Exploratory ..................................................................................................................24  
5 STUDY DESIGN ..................................................................................................................25  
5.1 Overall Investigation Plan ............................................................................................25  
5.1.1  Safety assessment  ...........................................................................................25  
5.1.2  Tumor to Background Ratio ...........................................................................25  
5.2 Eligibility Crite ria ........................................................................................................26  
5.2.1  Inclusion Criteria  ............................................................................................26  
5.2.2  Exclusion Criteria  ...........................................................................................26  
5.3 Study Assessments  .......................................................................................................27  
5.4 Patient Discontinuation Criteria  ...................................................................................27  
5.5 Replacement of Dropouts ............................................................................................27  
5.6 Study Drug Information and Dosage  ...........................................................................27  
5.6.1  Identific ation and Description of Test Article ................................................27  
5.6.2  Packaging and Labeling  .................................................................................28  
5.6.3  Storage and Handling of Test Article .............................................................28  
5.6.4  Study Drug Administration  ............................................................................28  
5.6.5  Camera/Imaging System  ................................................................................29  
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 16 of 111 5.6.5.1  Summary of the Camera/Imaging System Requirements  ..............29  
5.6.5.2  Quality System Requirements ........................................................30  
5.7 Concomitant Medications ............................................................................................31  
5.7.1  Allowed Medications......................................................................................31  
5.7.2  Prohibited Medications ...................................................................................31  
5.8 Schedule of Events .......................................................................................................31  
5.8.1  Measurement and Evaluations ........................................................................31  
5.8.1.1  Visit 1 (Screening, up to Day -28) .................................................31  
5.8.1.2  Visit 2 - Day of Surgery (Day 1):  ...................................................32  
5.8.1.3  Visit 3 -Follow-up (Day 7 [± 4]): ...................................................36  
5.8.1.4  Visits 4 -Follow-up (Day 28 [±4]): .................................................36  
5.8.2  Surgical Reporting Schematic  ........................................................................37  
5.8.3  Post-Surgery Questionnaire ............................................................................37  
5.8.4  Pathology Samples .........................................................................................37  
5.8.5  Camera/Imaging System E xposure ................................................................37  
6 STUDY ENDPOINTS  ..........................................................................................................38  
6.1 Efficacy  ........................................................................................................................38  
6.2 Secondary Efficacy  ......................................................................................................38  
6.3 Exploratory ..................................................................................................................39  
6.4 Safety  ...........................................................................................................................39  
7 PROCEDURES FOR REPORTING ADVERSE EVENTS  .............................................40  
7.1 Adverse Events Definitions .........................................................................................40  
7.2 Adverse Device Effe cts Definitions .............................................................................40  
7.2.1  Adverse Device Effect  ....................................................................................40  
7.2.1.1  Suspected Adverse Device Effect  ..................................................41  
7.2.1.2  Unanticipated Adverse Device Effect  ............................................41  
7.3 Reporting of Adverse Events .......................................................................................41  
7.3.1  Adverse Events  ...............................................................................................41  
7.3.2  Laboratory Abnormalities  ..............................................................................41  
7.3.3  Serious Adverse Events ..................................................................................42  
7.3.4  Reporting of Pregna ncies  ...............................................................................42  
7.3.5  Disease Progression  ........................................................................................42  
1.1.1  Overdoses .......................................................................................................42  
7.4 Classification of Adverse Events by Severity  ..............................................................42  
7.5 Classification of Adverse Events by Relationship to Study Drug Administration  ......43  
7.6 Adverse Events Qualifying for Expedited Reporting ..................................................43  
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 17 of 111 8 DATA RECORDING, CRF PROCESSING, AND STATISTICAL ANALYSIS  ..........44  
8.1 Data Recording and CRF Processing  ...........................................................................44  
8.2 Statistical Methods  .......................................................................................................44  
8.2.1  Sample Size Estimation  ..................................................................................44  
8.2.2  Analysis Sets  ..................................................................................................45  
8.2.3  Description of Subgroups to be Analyzed  ......................................................45  
8.2.4  Patient Demographics, Baseline Disease Status, and Disposition  .................46  
8.2.5  Statistical Analysis  .........................................................................................46  
8.2.5.1  Primary Efficacy Endpoints ...........................................................46  
8.2.5.2  Secondary Efficacy Endpoint ........................................................47  
8.2.5.3  Safety Evaluations  .........................................................................47  
8.2.5.4  Imaging System  .............................................................................48  
8.2.5.5  Prior and Concomitant Medications ..............................................48  
8.2.5.6  Handling of Missing Data, Subject Withdrawals, and Treatment 
Failures  ...........................................................................................49  
8.2.5.7  Interim Analyses  ............................................................................49  
9 ETHICS  .................................................................................................................................50  
9.1 Patient Information and Consent  .................................................................................50  
9.2 Institutional Review Board  ..........................................................................................50  
10 STUDY ADMINISTRATION .............................................................................................51  
10.1  Data  ..............................................................................................................................51  
10.2  Study Record Retention ...............................................................................................51  
10.3  Patient Anonymity  .......................................................................................................51  
10.4  Publications ..................................................................................................................51  
11 INVESTIGATOR’S STATE MENT  ...................................................................................52  
12 REFERENCES  .....................................................................................................................53  
APPENDICES  ............................................................................................................................. 54  
Table of Figures  
Figure 1.  TBR Imaging  .......................................................................................................... 25  
Figure 2.  Excitation and Emission Spectra of OTL38 ........................................................... 29  
Figure 3.  Classification Table  ................................................................................................ 46  
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 18 of 111 List of Abbreviations 
Abbreviation  Definition  
ADE  Adverse Device Effect  
AE Adverse Event  
AEL  Accessible Emission Limits  
ALT (SGPT)  Alanine aminotransferase ( serum glutamic pyruvate transaminase ) 
AST (SGOT)  Aspartate aminotransferase (serum glutamic oxaloacetic transaminase)  
BUN  Blood urea nitrogen  
CFR  Code of Federal Regulations  
CSE Clinically Significant Event  
EC Ethics Committee  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
FDA  United States Food and Drug Administration  
FITC  Fluorescein isothiocyanate  
FN False Negative  
FP False Positive  
FR Folate Receptor  
GCP  Good Clinical Practice  
  
IB Investigator Brochure  
ICH International Conference on Harmonisation  
IND Investigational New Drug  
IRB Institutional Review Board  
MedDRA  Medical Dictionary for Regulatory Activities  
SAE  Serious adverse event  
SUSAR   Suspected unexpected serious adverse reaction  
TAM  Tumor Associated Macrophages  
TEAE  Treatment Emergent Adverse Event  
TN True Negative  
TP True Positive  
ULN  Upper limit of the normal range  
WHO World Health Organization  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 26 of 111 5.2 Eligibility Criteria  
5.2.1 Inclusion Criteria 
To be considered eligible to participate in this study, a patient must meet all the inclusion criteria 
listed below : 
1. Male and Female patients  18 years of age and older 
2. Confirmed diagnosis of adenocarcinoma of the lung,  
OR, 
3. Have a primary diagnosis/high clinical suspicion of lung nodule(s) warranting surgery based on CT and/or PET imaging. 
4. Scheduled to undergo endoscopic or thoracic surgery 
5. A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential 
6. Female patients of childbearing potential or less than 2 years postmenopausal a gree to use 
an acceptable form of contraception from the time of signing informed consent until 30 days after study completion  
7. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments 
5.2.2 Exclusion Criteria 
Patients will be excluded if they meet any of the exclusion criteria listed below: 
1. Previous exposure to OTL38 
2. Known FR-negative lung nodules.  
3. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient  
4. History of anaphylactic reactions  
5. History of allergy to any of the components of OTL38, including folic acid 
6. Pregnancy, or positive pregnancy test 
7. Clinically significant abnormalities on electrocardiogram (ECG) at screening.  
8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 
9. Impaired renal function defined as eGFR< 50 mL/min/1.73m
2 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 27 of 111 10. Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST),  alkaline phosphatase ( ALP), 
or total bilirubin.  
11. Received an investigational agent in another investigational drug or vaccine trial within 
30 days prior to surgery. 
12. Known sensitivity to fluorescent light 
5.3 Study Assessments  
The assessments for this study are listed in  Section  5.8. 
5.4 Patient Discontinuation Criteria  
Although a single dose of study dr ug is infused on Day 1, a patient may be withdrawn from the 
study for any of the following reasons: 
• Request of the patient  or patient’s representative  
• AEs or adverse device effects (ADEs)  based on the judgment of the Investigator 
• The Investigator decides that it is in the patient’s best interest  
• The patient is noncompliant with the protocol 
• Lost to follow-up 
• Death  
If a subject  is withdrawn at any time, the reason(s) will be recorded on the relevant page of the 
electronic case report form (eCRF).  
Patients discontinued due to AEs or ADEs will be monitored until resolution or stability of the 
event  based on the judgment of the investigator. 
5.5 Replacement of Dropout s 
Patients withdrawing for reasons other than AEs  or any other tolerability issues with the treatment 
may be replaced.  
5.6 Study Drug Information and Dosage   
5.6.1 Identification and Description of Test Article 
OTL38 will be supplied in vials containing 1.6 mL of solution of 2 m g/mL OTL38 for a total of 
3.2 mg of drug per vial.  
Study medication should be stored in a freezer  and with protection from 
light ( see Site Study Reference Manual ). 

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 40 of 111 7 PROCEDURES FOR REPORTING ADVERSE EVENTS 
7.1 Adverse Events Definitions 
The investigator will monitor the occurrence of AEs during the course of the study that will end 
with Visit 4.  
The following definitions of terms are guided by the United States Code of Federal Regulations (21 CFR 312.32(a)) and are included here.  
Adverse event  is any untoward medical occurrence in a patient associated with the use of a drug 
in humans, whether or not considered drug related. 
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, "reasonable 
possibility" means there is evidence to suggest a causal relationship between the drug and the 
adverse ev ent. Suspected adverse reaction implies a lesser degree of certainty about causality than 
adverse reaction, which means any adverse event caused by a drug.  
Unexpected adverse event (adverse drug experience) or (suspected) adverse reaction means any 
adverse event  or (suspected) adverse reaction  that is not listed in the investigator brochure or is 
not listed at the specificity or severity that has been observed. 
An AE or suspected adverse reaction is considered “serious” if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes: Death, a life- threatening 
adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life -
threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, t hey may  jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. 
An adverse event is considered “life- threatening” if, in the view of either the investigator or 
sponsor, its occurrence place s the patient at immediate risk of death. It does not include an 
adverse event that, had it occurred in a more severe form, might have caused death. Suspected  Unexpected Serious Adverse Reaction (SUSAR) is any (suspected) adverse reaction 
(any adverse even t for which there is a reasonable possibility that the drug caused the adverse 
event) that is both serious and unexpected. 
7.2 Adverse Device Effects Definitions  
7.2.1 Adverse Device Effect  
An ADE is defined as any untoward and unintended response to a medical device, in this study, 
the camera/ imaging system.  This definition includes any event resulting from insufficiencies or 
inadequacies in the instructions for use or the deployment of the device, as well as any event that is the result of a user error [ISO 14 155-1:2003 (E) 3.1]. 
All ADEs noted during the study will be reported in the eCRF. 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 41 of 111 7.2.1.1  Suspected Adverse Device Effect 
A suspected ADE is a subset of all ADEs for which there is a reasonable possibility (i.e. , evidence 
to suggest a causal relationship between the device and the ADE) that the device caused the event. 
Suspected ADE implies a lesser degree of certainty about causality than adverse device effect.  
7.2.1.2  Unanticipated Adverse Device Effect 
An unanticipated ADE is any serious adverse effect on health or saf ety or any life -threatening 
problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application , or any other unant icipated serious problem associated with a device that relates to the 
rights, safety, or welfare of subjects [21 CFR 812.3 (s)]. 
7.3 Reporting of Adverse Events  
7.3.1 Adverse Events 
The safety of all patients enrolled in this study will be recorded from the time of study drug 
administration  and throughout the course of the study that will end with Visit 4.  
All AEs will be recorded in the appropriate section of the eCRF.  Patients withdrawn from the 
study because of AEs will be followed by the investigator until the outcome is determined.  When 
appropriate, additional written reports and documentation will be provided. 
All AEs beginning after the exposure to study drug must be reported to the sponsor or its designee 
if the onset of the AE was before Visit 4. All AEs that are judged by the investigator to be not related to study drug need not be reported to the sponsor or its designee after Visit 4.  All AEs that 
are judged by the Investigator to be at least possibly related to study drug administration must be reported to the sponsor or its designee regardless of how much time has elapsed since the last exposure to study drug. 
7.3.2 Laboratory Abnormalities 
To the extent possible, all clinically significant laboratory abnormalities observed during the 
course of the study will be included under a reported AE describing a clinical syndrome (e.g.,  elevated blood urea nitrogen and creatinine in the setting of an AE of “renal failure” or 
elevated ALT/AST in the setting of an AE of “hepatitis”).  In these cases (e.g., an AE of renal 
failure), the laboratory abnormality itself (e.g., elevated creatinine) does not need to be recorded 
as an AE.  
In the absence of a reported AE identifying a clinical syndrome that encompasses the observed clinically significant laboratory abnormality that “isolated” laboratory abnormality itself should 
be reported as an AE.  
Patients experiencing AEs or laboratory abnormalities will be assessed and appropriate evaluations performed until all parameters have returned to baseline levels, or are consistent with  
the patient’s then -current physical condition, in the opinion of the investigator. 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 42 of 111 7.3.3 Serious Adverse Events 
Instructions for reporting Serious Adverse Events (SAE) and Suspected Unexpected Serious 
Adverse Reactions (SUSAR) are found on P age 2. A written report of all SAEs that occur after 
the administration of study drug and during the study (ending with Visit 4) must be submitted to 
the IRB/ethics committe e (EC) and the Sponsor. SAEs/SUSARs  must be reported to the Sponsor 
within 24 hours for a determination of expedited reporting to FDA, as described in Section  7.6. In 
all SAE  reports, the investigator will advise whether or not the SAE is  judged to be related to 
study drug administration.  SAEs that occur after Visit 4  and are not reasonably associated with 
study drug do not require reporting per the instructions given below. All SAEs that are judged by 
the investigator to be at least possibly related to study drug administration must be reported to the sponsor or its designee regardless of how much time has elapsed since the last exposure to study drug. All AEs must be submitted to the IRB/EC in an annual report.  
7.3.4 Reporting of Pregnancies 
If a patient becomes pregnant during the course of the study, the investigator or site personnel must notify the Medical monitor (see Page  3 for details) within 5  working days after the  
investigator or site personnel become aware of the pregnancy.  If an SAE occurs in conjunction 
with the pregnancy, then the reporting time frame for an SAE must be met.  
7.3.5 Disease Progression 
The progression of lung cancer (in patients diagnosed as such) per se will not constitute an AE. 
However, if the progression of the lung cancer meets the criteria for an SAE , then it should be 
reported  as an SAE ( see Page 2). 
1.1.1 Overdoses 
Overdoses should be reported as a protocol violation. If an overdose results in an AE, the CRF AE page should be completed, and source documents included. If the overdose results in an SAE, then SAE reporting should be followed using the specific CRF pages with overdose information entered in the narrative s ection. All available clinical information relevant to overdose, including 
signs and symptoms, laboratory findings, and therapeutic measures or treatments administered, should be summarized and discussed. 
7.4 Classification of Adverse Events by Severity  
The in vestigator must categorize the severity of each AE according to the following: 
• Mild: Awareness of signs or symptoms, but easily tolerated and are of minor irritant type. Symptoms do not require therapy or a medical evaluation; signs and symptoms are transient.  
• Moderate: Events introduce a low level of inconvenience or concern to the participant, but are usually improved by simple therapeutic measures; moderate experiences may cause some interference with functioning 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 43 of 111 • Severe:  Events generally require systemic drug therapy or other treatment; they are 
usually incapacitating  
• Life-Threatening:  Risk of imminent death requiring immediate intervention.  
7.5 Classification of Adverse Events by Relationship to Study Drug 
Administration  
The relationship of each AE t o the study drug administration will be assessed by the investigator; 
after careful consideration , according to the following guidelines: 
Definitely Related: An adverse event that has a timely relationship to the administration of the 
study drug and follows a known pattern of response for which no alternative cause is present  
Probably Related: An adverse event that has a timely relationship to the administration of the 
study drug and follows a known pattern of response, but for which a potential alternative cause may be present  
Possibly Related: An adverse event that has a timely relationship to the administration of the study drug, follows no known pattern of response, but a potential alternative cause does not exist 
Not related: An adverse event for which  there is evidence that it is definitely related to a cause 
other than the study; in general, no timely relationship to the administration of the drug exists, or 
if so, the event does not follow a pattern of response and an alternative cause is present 
7.6 Adverse Events Qualifying for Expedited Reporting   
All SUSARs , SAEs and unanticipated adverse device effects must be reported to On Target 
Laboratories  or designee by telephone and in writing as soon as pr actical, but at least within 
24 hours of initial repor t. 
The investigator must report fatal and life-threatening SUSARs to the IRB within 7 calendar days 
of the initial receipt of information. On Target Laboratories or designee will report fatal and life -
threatening SUSARs to the regulatory authorities and al l investigators within 7 calendar days of 
the initial report of information.  
The investigator must report non-fatal and non- life-threaten ing SUSARs to the IRB within 
15 calendar days of the initial receipt of information. On Target Laboratories or designee will report non-fatal and non- life-threatening SUSARs to the regulatory authorities and all 
investigators within 15 calendar days of the initial report of information. 
The investigator must report all unanticipated adverse devi ce effects to the IRB within  
10 calendar days of the initial receipt of information. On Target Laboratories or designee will report all unanticipated adverse device effects to the regulatory authorities and all investigators within 10 working days of the initial report of information. 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 48 of 111 8.2.5.3.2 Clinical Laboratory Evaluations 
The analys is of laboratory parameters will include descriptive statistics for the change from 
baseline to each post- baseline study visit as well as shifts from baseline to each post- baseline 
study visit for categorical lab parameters . In addition, shift tables (i.e., low-normal- high at 
baseline versus low-normal-high at last visit will be provided where appropriate. Urinalysis and 
pregnancy results will not be summarized but will be provided in a data listing . For all relevant 
laboratory data, values above or below normal limits will be flagged along with the direction of 
abnormality in line listings . 
8.2.5.3.3 Vital Signs 
Vital signs will be summarized via descriptive statistics similar to that described above for 
clinical laboratory evaluations  with regard to changes from bas eline . 
8.2.5.3.4 Physical Examination 
Physical examination results will be provided in line listings only.  
8.2.5.3.5 Electrocardiogram 
Electrocardiogram results will be provided in line listings only.  
8.2.5.3.6 Pathology and Immunohistochemistry 
Pathology and immunohistochemistry resul ts will be provided in line listings.  
8.2.5.4  Imaging System 
Times on and off for the imaging system for each subject will be provided in line listings.  
8.2.5.5  Prior and Concomitant Medications 
The prior and concomitant medications will be coded to identify the drug class and preferred drug 
name. Concomitant medications will include all medications that started, or were continuing, 
during or after administration of the study drug. Prior medications will include all recorded 
medications  and supplements a patient was taking  during the screening period that were  stopped 
prior to administration of the study drug. 
The number and percent of subjects using concomitant medications will be tabulated by drug 
class and preferred drug name for all subjects in the safety analysis set . If a subject has more than 
one medication within a drug class, the subject will be counted only once in that drug class. If a 
subject has more than one medication that codes to the same preferred drug name, the subject will be counted only once for that pr eferred drug name . All percentages will use the number of 
subjects in the safety analysis set as the denominator . The tabular summary will be sorted by 
descending order of overall incidence for concomitant medications only. Prior medications will be presen ted in line listings only . Concomitant medications will also be provided in line listings. 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 50 of 111 9 ETHICS 
The study will be conducted in compliance with applicable ICH guidelines, the ICH E6 GCP 
guideline, and regulations, guidelines, and applicable laws of the locale and countries where the 
study is conducted. The study will be conducted with the approval of a duly constituted IRB/EC 
in accordance with the requirem ent of United States regulation Title 21 CFR Part 56 - 
Institutional Review Boards. The nature and risks of the study will be fully explained to each 
patient and written consent obtained in accordance with the requirements of 21 CFR 50 - 
Protection of Human Subjects. Patients will be informed of their rights, including the right to 
withdraw from the study at any time.  
9.1 Patient Information and Consent  
A properly executed, written informed consent in compliance with national and local regulations 
and GCP guidelines will be obtained from each patient prior to entering the study or performing 
any study- related procedures that are not part of the patient ’s standard care . The Investigator will 
submit a copy of the informed consent document to the IRB/EC for review and approval before patients  are enrolled. The Investigator will provide a copy of the signed informed consent to the 
patient and the original will be maintained in the patient’s medical record.  
9.2 Institutional Review Board  
The Investigator will provide the IRB/EC with all requisite material, including a copy of the 
protocol, IB, and the informed consent document . The study will not be initiated until the IRB/EC 
provides written approval of the protocol and the informed consent document and until approved documents have been obtained by the Investigator, and copies received by the Sponsor. Appropriate reports on the progress of this study by the Investigator will be made to the IRB/EC and the Sponsor in accordance with the applicable government regulations and in agreement with the Sponsor. 
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 52 of 111 11 INVESTIGATOR’S STATEMENT  
I have read the protocol entitled “A Phase 2, Single dose, Open- Label, Exploratory Study to 
Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate 
Receptor Positive Lung Nodules ” and agree that it contains all necessary details for carrying out 
the study as described.  I will conduct this protocol as outlined therein and will make a reasonable 
effort to complete the study within the time designated.  I will provide copies of the protocol and 
access to all information furnished by On Target Laboratories, Inc. to study personnel under my 
supervision. I will discuss this material with them to ensure they are fully informe d about the drug 
and the study. I understand that the study may be terminated or enrollment suspended at any time 
by On Target Laboratories, Inc., with or without cause, or by me if it becomes necessary to protect 
the best interests of the study patients . 
 
Signature of Investigator  Date (day/month/year) 
Printed Name of Investigator  Site Number  
On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 58 of 111 Appendix 2  Detailed Description of the  
 
 
 
 
 
  
          
 
  
  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 71 of 111 Appendix 3  Detailed Description of the  
 
 
 
 
 
  
          
 
       
  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 82 of 111 Appendix 4  Detailed Description of the  
 
 
 
 
 
  
          
 
      
  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 95 of 111 Appendix 5  Detailed Description of the  
 
 
 
 
 
  
          
 
  
  
  
  
  
  
  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 107 of 111 Appendix 6 Surgical Reporting Schematics  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018  
Confidential  Page 108 of 111 

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 109 of 111 Appendix 7  Investigator Questionnaire  

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 110 of 111 

On Target Laboratories, Inc. Protocol OTL -2016 -OTL38 -005 
Version 5.0, 14 June 2018   
Confidential  Page 111 of 111 
